Piper Sandler analyst Kelsey Goodwin raised the firm’s price target on Revolution Medicines (RVMD) to $172 from $120 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 earnings along with a corporate update that was largely in line with prior guidance across their various RAS(ON) inhibitor programs.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $205 from $175 at Guggenheim
- Ami Fadia Reiterates Buy on Revolution Medicines, Slightly Lowers Price Target to $183 Amid Higher Non‑Cash Expenses and Expanded RASolute 301 Trial
- Revolution Medicines reports Q1 EPS ($2.29), consensus ($1.84)
- Revolution Medicines sees FY26 operating expenses of $1.7B-$1.8B
- Revolution Medicines announces NEJM publication of data on Daraxonrasib